

# Structural and Functional Features of Pyridoxal Phosphate-Binding Protein

Subjects: **Biochemistry & Molecular Biology**

Contributor: Lorena Tremiño , Antonio Llop , Vicente Rubio , Asunción Contreras

The pyridoxal phosphate-binding protein (PLPBP) family (also termed ProSC/PROSC or COG0325 family) members are found in all kingdoms of life, exemplified by the proteins YBL036C (yeast), YggS (Gram-negative bacteria), YImE (Gram-positive bacteria), PipY (cyanobacteria), PLPHP (humans) and HTH5 (rice).

cyanobacteria

nitrogen regulation

COG0325

PLPHP

PLPBP

## 1. Introduction

Cyanobacteria, phototrophic organisms performing oxygenic photosynthesis, constitute an ecologically and biotechnologically important phylum, responsible for the evolution of the oxygenic atmosphere, being the main contributors to marine primary production <sup>[1]</sup>. Their photosynthetic lifestyle and ease of cultivation make them ideal production systems for several high-value compounds, including biofuels <sup>[2]</sup>. Despite important breakthroughs in the genetic analysis of cyanobacteria, there is still a remarkable proportion of genes of unknown function in this phylum, many of which are presumably relevant to the biology of cyanobacteria.

The cyanobacterium *Synechococcus elongatus* PCC7942 (hereafter *S. elongatus*), the only photosynthetic organism for which the contribution of each gene to fitness has been evaluated so far <sup>[3]</sup>, is being used as a model system to address fundamental questions concerning the photosynthetic lifestyle. More recently, the *S. elongatus* genome has been used as the reference organism to create a database for the Cyanobacterial-Linked Genome <sup>[4]</sup>, accessible through an interactive platform "<https://dfgm.ua.es/es/cyanobacterial-genetics/dclg/index.htm> (accesed on 1 August 2022)".

In bacteria and plants, 2-oxoglutarate (2-OG), a key metabolic signal of the intracellular carbon-to-nitrogen balance, is sensed by the highly conserved and widely distributed signal transduction protein PII. PII regulates the activity of proteins involved in nitrogen metabolism by direct protein–protein interactions <sup>[5]</sup>. In *S. elongatus* PII interacts with a small (89 residues) protein called PipX (PII-interacting protein X), which was initially identified in yeast two-hybrid analyses <sup>[6][7]</sup>.

PipX was also found in searches for proteins interacting with NtcA, the global transcriptional regulator involved in nitrogen assimilation in cyanobacteria <sup>[8]</sup>. PipX stabilizes the conformation of NtcA which is transcriptionally active and probably helps the local recruitment of RNA polymerase to NtcA-dependent promoters <sup>[9]</sup>. At low 2-OG concentrations corresponding to nitrogen-excess conditions, the sequestration of PipX by PII renders PipX

unavailable for NtcA binding and activation, reducing the expression of NtcA-dependent gene targets [9][10][11][12][13]. Partner swapping by PipX is enabled by its N-terminal Tudor-like domain (TLD/KOW), which provides contacts for both NtcA and PII. Complex formation with PipX increases the affinity of PII for ADP [9], and, conversely, the interaction between PII and PipX is highly sensitive to fluctuations in the ATP/ADP ratio [14]. Thus, PipX partner swapping between PII and NtcA integrates signaling of the carbon-to-nitrogen ratio and the energy status by PII with the regulation of nitrogen-responsive genes controlled by NtcA [10][15][16].

Interestingly, a high PipX/PII ratio prevents growth [11][17] and, consistent with this, cyanobacterial genomes always contain at least as many copies of *glnB* as of *pipX* [18], suggesting that a relatively high ratio of PII over PipX is required to counteract unwanted interactions with low-affinity PipX partners.

In *S. elongatus* *pipX* is co-transcribed with the downstream gene *pipY*. This last gene belongs to the widely distributed and highly conserved pyridoxal phosphate (PLP)-binding protein (COG0325/PLPBP) family that is involved in vitamin B<sub>6</sub> and amino acid homeostasis [19]. The PLPBP family (also termed ProSC/PROSC or COG0325 family) members are found in all kingdoms of life, exemplified by the proteins YBL036C (yeast), YggS (Gram-negative bacteria), YImE (Gram-positive bacteria), PipY (cyanobacteria), PLPHP (humans) and HTH5 (rice). These are all single-domain proteins exhibiting the fold type III of PLP-holoenzymes [20][21][22][23][24] with no known enzymatic activity.


## 2. Structural and Functional Features of PLPBP

### 2.1. PLP Is Solvent-Exposed in PLPBP Structures

The vitamin B<sub>6</sub> vitamer PLP is used as a cofactor for enzyme-catalyzed reactions which include transamination, decarboxylation, racemization, aldol cleavage, or replacement reactions among others [25]. Since amino acid metabolism and other essential processes require PLP-dependent enzymes [26][27], PLP availability is of paramount importance to supply cofactors to activate newly synthesized apo-B<sub>6</sub> enzymes. PLP is also required as a cofactor of glycogen phosphorylase [28] and certain transcriptional factors and regulators [27]. However, its aldehyde group endows PLP with high chemical reactivity, sometimes causing the inactivation of proteins (see for example, [29]), and therefore additional mechanisms are required for keeping the levels of free PLP low in cells and tissues. In the first report of a member of this family, Eswaramoorthy et al. (2003) documented structural parallelisms between the yeast protein YBL036C and the N-terminal domain of alanine racemases, leading them to infer (and even to provide some experimental hints for it) that PLPBP had alanine racemase activity [21]. However, no amino acid racemase, decarboxylase, deaminase, or transaminase activities were found for *E. coli* or human proteins [30], and although crystal structures of alanine racemase with bound substrates (D-ala) or inhibitors (D-cycloserine) have been determined [31], extensive crystallization attempts with these molecules did not detect any binding to PipY [22]. Furthermore, in vivo work did not support alanine racemase activity for *S. elongatus* PipY [19]. Therefore, despite the key importance of the PLP cofactor for PLPBP function (see below), PLP appears to have no catalytic function in the PLPBP family.

Structures of six PLPBP members have been determined and deposited in the Protein DataBank (PDB, "<https://www.rcsb.org/> (accesed on 1 September 2022)") (Table 1). All of these structures correspond to single-domain chains folded according to the triose phosphate isomerase (TIM) barrel typically found in the fold type III of PLP-dependent enzymes. The only ones reported to date from a eukaryotic organism correspond to yeast protein YBL036C. The others are from a Gram-positive bacterium (*Bifidobacterium adolescentis*), and four Gram-negative bacteria including the cyanobacterium *S. elongatus* (Table 1). *S. elongatus* PipY structures with and without PLP offer high resolution and have been used to estimate the effects of clinical missense mutations found in the *PLPBP* human gene in patients with vitamin B<sub>6</sub>-dependent epilepsy [22][23]. Here, researchers use PipY as a reference for the additional discussion on structural and functional details concerning studied members of the protein family.

**Figure 1** shows the structure of PipY containing PLP (PDB file 5NM8).




**Figure 1.** Structure of PipY from *S. elongatus* (PDB 5NM8) colored for the evolutionary conservation of residues among PLPBP homologs, and mapping therein, residues targeted by missense mutations. The structure is in a cartoon representation except for the PLP, which is in a stick representation with C, O, N, and P atoms in yellow, red, blue, and orange, respectively. Color-coding of the structure from cyan to magenta according to the residue conservation score (the higher, the more conserved) given by The ConSurf Server "URL [https://consurf.tau.ac.il/consurf\\_index.php](https://consurf.tau.ac.il/consurf_index.php) (accesed on 3 August 2022) when queried with chain A of the PDB 5NM8, with default parameters. Spheres mark the location in PipY of known human PLPBP mutations (see Table 2). Residue numbers are given in one letter code, in black for *S. elongatus*, and shown in red, green, and blue, the human mutations causing vitamin B<sub>6</sub>-dependent epilepsy, and the in vitro mutations obtained in the corresponding proteins of *F. nucleatum*, and *E. coli*, respectively.

**Table 1.** Structures of COG0325/PLPB family proteins were determined and deposited in the Protein DataBank (PDB).

Organism	Protein	PDB File	Vitamer	Ligands	Amino Acid Changes	Resolut. (Å)	Deposition Year	Ref.
<i>Escherichia coli</i>	YggS	1W8G	PLP	Isocitrate	None	2.00	2004	—
		3SY1	PLP	MES Acetate	L32V/G56S/N58H/H81N/I83A/H102I/M165S/S202A/M205Q/R221A hexamutant	1.47	2011	—
		7UBQ	PNP *	None	None	2.60	2022	—
		7UB4	PLP	None	K36A/K38A/K233A/K234	2.40	2022	—
		7UAX	None	PO <sub>4</sub> H <sub>3</sub>	K36A/K38A	2.07	2022	—
		7U9H	None	SO <sub>4</sub> H <sub>2</sub>	None	2.00	2022	—
		7UBP	PLP	SO <sub>4</sub> H <sub>2</sub>	K36A/K137A	2.30	2022	—
		7UB8	PLP	Butanediol	K38A/K137A/K233A/K234A	2.30	2022	—
		7UAU	PLP	SO <sub>4</sub> H <sub>2</sub>	K137A	2.10	2022	—
		7UAT	PLP	PO <sub>4</sub> H <sub>3</sub>	K36A	2.00	2022	—
		7U9C	PLP	PO <sub>4</sub> H <sub>3</sub>	None	2.10	2022	—
<i>Bifidobacterium adolescentis</i>	YggS	3CPG	PLP	Acetate	Se-Met **	1.71	2008	—
<i>Agrobacterium tumefaciens</i>	YggS	3R79	PLP	Acetate Pr <sup>+3</sup>	Se-Met **	1.90	2011	—
<i>Synechococcus elongatus</i>	PipY	5NLC	None	PO <sub>4</sub> H <sub>3</sub>	None	1.90	2017	[22]
		5NM8	PLP	Ca <sup>2+</sup>	None	1.93	2017	[22]
<i>Fusobacterium nucleatum</i>	YggS	7F8E	None	SO <sub>4</sub> H <sub>2</sub>	Se-Met **	2.08	2021	—
		6KZW	None	PO <sub>4</sub> H <sub>3</sub>	T5A/N202S, Se-Met **	2.08	2019	—
		7YGF			Structure not released	2.08	2022	[24]
<i>Saccharomyces cerevisiae</i>	YBL036C	1CT5	PLP	None	Se-Met **	2.00	1999	[21]
		1B54	PLP	None	None	2.10	1999	[21]

The TIM-barrel fold, initially described for triosephosphate isomerase [32], is a highly widespread protein fold, generally reported as consisting of eight  $\alpha$  helices that alternate with parallel  $\beta$  strands of a circularly closed  $\beta$ -sheet, in which the helices encircle the sheet (reviewed in [33]). The TIM-barrel of PLP proteins, first described for alanine racemase [31], characterizes the fold type III of PLP-dependent enzymes and presents an extra N-terminal  $\alpha$  helix preceding the first of the eight  $\beta$ -repeats. However, while this modified TIM-barrel is part of a two-domain subunit forming homodimers in alanine racemase, ornithine decarboxylase, and the broad specificity amino acid racemase [20][25][34], PLPBP members are single-domain proteins that appear to be mainly monomers (but see discussion below) ([21][22]; and other PDBs in **Table 1**).

While PLP is found in PLPBP structures in the same location that it is found in the fold type III of PLP enzymes, in all PLPBP structures the PLP cofactor is solvent-exposed and highly accessible, thus being appropriately positioned for a role of PLPBP as a PLP delivering device in cells. In this context, the role of the C-terminal  $\alpha$  helix (helix 9) of PipY in anchoring the phosphate of PLP, and the relatively large changes in helix 9 orientation depending on the presence or absence of PLP have led to the hypothesizing [22] that this helix may have a role in being a trigger for the binding and release of PLP (Figure 2).



**Figure 2.** PipY structures with and without PLP illustrate the two positions of helix 9. Cartoon representation of PipY structure from *S. elongatus* complexed with PLP (PDB 5NM8) and PipY-Apo form (PDB 5NLC), with  $\alpha$ -helix 9 shown in blue and green, respectively. Inset: Displacement of  $\alpha$ -helix 9 observed in the PLP-containing form is highlighted by superimposing both protein forms. The PLP molecule is illustrated using stick representation, where C, O, N, and P atoms are colored yellow, red, blue, and orange, respectively.

The available data so far suggest that the proteins of this family might act as PLP carriers which supply the cofactor to PLP-dependent enzymes, shielding this cofactor from unwanted reactions with other molecules, although this has not been strictly proven and the mechanisms involved remain unclarified.

## 2.2. Dimerization of Just Some PLPBP Family Members?

While all available crystal structures are consistent with PLPBP family members being monomers, size-exclusion chromatography of human PLPHP, performed in two different studies [23][35] revealed a second peak corresponding to dimers. In [23], the minor peak was shown to depend on disulfide bridges, a result interpreted as PLPHP being mainly monomeric with the possibility of stable dimerization via the formation of a disulfide bridge between exposed cysteines. Consistent with this, human mutation Tyr69Cys increased dimer formation (Table 2). However, Fux and Sieber [35] challenged this view, reporting that their PLPHP preparation was predominantly dimeric even under reducing conditions [35]. They also suggested that discrepancies with the previous work may be due to differences in expression strains or purification strategies. It is worth noting that while the human protein contains five cysteine residues, the amino acid chains of *S. elongatus* PipY and *E. coli* YggS have just one or two cysteines, respectively, and thus they would be less prone to making disulfide bonds under oxidative conditions.

**Table 2.** Missense mutations reported in human PLPHP associated with vitamin B6-dependent epilepsy, as well as two experimental mutations in orthologous bacterial proteins. Molecular mechanisms of damage.

Amino Acid Change in HuPLPHP						Molecular Mechanism: Effect on PLPBP Protein		
Amino acid	Conserv. Score <sup>1</sup>	Change	Clinical effects	Reported in	Number of patients	Observed effect	Inferred from	Ref.
P40	7	P40L	Seizures	[36] [37]	1 (P40L/R241Q) 1 (P40L/splicing)	↓ thermostability	In vitro studies on rHuPLPHP	[23]
R41	4	R41Q	Seizures Mild disease <sup>2</sup>	[38] [39]	2 (homozygous;R41Q/V45D) 3 (homozygous)	↓ yield/misfolding? ↓ thermostability	In vitro studies on rHuPLPHP	[35]
		R41W	Seizures, death	[40]	1 (homozygous)	NT	NT	NT
V45	9	V45D	Seizures	[38]	1 (R41Q/V45D)	↓ PLP content ↓ thermostability	In vitro studies on rHuPLPHP	[35]
K47	9	K47A	Not reported in humans (prenatally lethal?)			lack of PLP	rEcyygS <sup>K36A</sup>	[30]
E67	9	E67K	Seizures Severe disease <sup>2</sup>	[38] [39]	1 (homozygous) 3 (homozygous)	Misfolding	In vitro studies on rHuPLPHP	[35]
Y69	7	Y69C	Seizures Moderate disease <sup>2</sup>	[36]	1 (homozygous)	Higher dimerization ↓ PLP content	In vitro studies on rHuPLPHP	[23]
P87	1	P87L	Seizures Severe disease <sup>2</sup>	[41] [36] [42]	1(P87L/R241Q) 1 (homozygous) 1 (P87L/splicing)	↓ solubility/misfolding	In vitro studies on rHuPLPHP	[23]
I94	8	I94F	Seizures Mild disease <sup>2</sup>	[39]	1 (homozygous)	Proposed ↓ in PLP saturation	Structural modeling of HuPLPHP	[39]
M113	6	M113T	Seizures	[37]	1 (M113T/C15X)	NT	NT	NT
T116	7	T116I	Seizures Severe disease <sup>2</sup>	[39]	2 (1 homozygous; 1 homozygous (T116I/H275D))	Proposed ↓ in PLP saturation	Structural modeling of HuPLPHP	[39]
L175	6	L175P	Seizures Severe disease <sup>2</sup>	[41]	1 (homozygous)	Misfolding	In vitro studies on rHuPLPHP	[23]
R205	7	R205Q	Seizures Moderate disease <sup>2</sup>	[36] [38]	1 (R205Q/null) 1 (homozygous)	↓ thermostability	In vitro studies on rHuPLPHP	[23]

Amino Acid Change in HuPLPHP						Molecular Mechanism: Effect on PLPBP Protein		
G224	9	G224A	Seizures Severe disease <sup>2</sup>	[39]	1 (G224A/splicing)	Proposed ↓ in PLP saturation	Structural modeling of HuPLPHP	[39]
S226	9	S226A	Not reported in humans (prenatally lethal?)			↓PLP saturation	rFn <sup>S201A</sup>	[24]
R241	9	R241Q	Seizures	[41] [36] [43]	1 (P87L/R241Q) 1 (P40L/R241Q) 1(R241Q/splicing)	↓solubility ↓thermostability ↓PLP binding	In vitro studies on rHuPLPHP In vitro studies on rSePipY <sup>R210Q</sup>	[22] [23]
I242	7	I242T	Seizures	[44]	1 (homozygous)	NT	NT	NT
H275	NA	H275D	Seizures	[39]	1 (homozygous T116I/H275D)	Variant of uncertain significance (VUS)	Structural modeling of HuPLPHP	[39]

## References

8. Herrero, A.; Muro-Pastor, A.M.; Flores, E. Nitrogen Control in Cyanobacteria. *J. Bacteriol.* 2001, 183, 411–425.
9. Llácer, J.L.; Espinosa, J.; Castells, M.A.; Contreras, A.; Forchhammer, K.; Rubio, V. Structural Basis for the Regulation of NtcA-Dependent Transcription by Proteins PipX and PII. *Proc. Natl. Acad. Sci. USA* 2010, 107, 15397–15402.
10. Forcada-Nadal, A.; Llácer, J.L.; Contreras, A.; Marco-Marín, C.; Rubio, V. The PII-NAGK-PipX-NtcA Regulatory Axis of Cyanobacteria: A Tale of Changing Partners, Allosteric Effectors and Non-Covalent Interactions. *Front. Mol. Biosci.* 2018, 5, 91.
11. Espinosa, J.; Castells, M.A.; Laichoubi, K.B.; Forchhammer, K.; Contreras, A. Effects of Spontaneous Mutations in PipX Functions and Regulatory Complexes on the Cyanobacterium *Synechococcus elongatus* Strain PCC 7942. *Microbiology* 2010, 156, 1517–1526.
12. Espinosa, J.; Forchhammer, K.; Contreras, A. Role of the *Synechococcus* PCC 7942 Nitrogen Regulator Protein PipX in NtcA-Controlled Processes. *Microbiology* 2007, 153, 711–718.
13. Laichoubi, K.B.; Espinosa, J.; Castells, M.A.; Contreras, A. Mutational Analysis of the Cyanobacterial Nitrogen Regulator PipX. *PLoS ONE* 2012, 7, e35845.
14. Zeth, K.; Fokinas, O.; Forchhammers, K. Structural Basis and Target-Specific Modulation of ADP Sensing by the *Synechococcus elongatus* PII Signaling Protein. *J. Biol. Chem.* 2014, 289, 8960–8972.
15. Espinosa, J.; Labella, J.I.; Cantos, R.; Contreras, A. Energy Drives the Dynamic Localization of Cyanobacterial Nitrogen Regulators during Diurnal Cycles. *Env. Microbiol.* 2018, 20, 1240–1252.
16. Labella, J.I.; Cantos, R.; Salinas, P.; Espinosa, J.; Contreras, A. Distinctive Features of PipX, a Unique Signaling Protein of Cyanobacteria. *Life* 2020, 10, 79.
17. Espinosa, J.; Castells, M.A.; Laichoubi, K.B.; Contreras, A. Mutations at PipX Suppress Lethality of PII -Deficient Mutants of *Synechococcus elongatus* PCC 7942. *J. Bacteriol.* 2009, 191, 4863–4869.
18. Laichoubi, K.B.; Beez, S.; Espinosa, J.; Forchhammer, K.; Contreras, A. The Nitrogen Interaction Network in *Synechococcus WH5701*, a Cyanobacterium with Two PipX and Two PII-like Proteins. *Microbiology* 2011, 157, 1220–1228.
19. Labella, J.I.; Cantos, R.; Espinosa, J.; Forcada-Nadal, A.; Rubio, V.; Contreras, A. PipY, a Member of the Conserved COG0325 Family of PLP-Binding Proteins, Expands the Cyanobacterial Nitrogen Regulatory Network. *Front. Microbiol.* 2017, 8, 1244.
20. Schneider, G.; Käck, H.; Lindqvist, Y. The Manifold of Vitamin B6 Dependent Enzymes. *Structure* 2000, 8, R1–R6.

21. Eswaramoorthy, S.; Gerchman, S.; Graziano, V.; Kycia, H.; Studier, F.W.; Swaminathan, S. Structure of a Yeast Hypothetical Protein Selected by a Structural Genomics Approach. *Acta Cryst. D Biol. Cryst.* 2003, 59, 127–135.

22. Tremiño, L.; Forcada-Nadal, A.; Contreras, A.; Rubio, V. Studies on Cyanobacterial Protein PipY Shed Light on Structure, Potential Functions, and Vitamin B6-Dependent Epilepsy. *FEBS Lett.* 2017, 591, 3431–3442.

23. Tremiño, L.; Forcada-Nadal, A.; Rubio, V. Insight into Vitamin B6-Dependent Epilepsy Due to PLPBP (Previously PROSC) Missense Mutations. *Hum. Mutat.* 2018, 39, 1002–1013.

24. He, S.; Chen, Y.; Wang, L.; Bai, X.; Bu, T.; Zhang, J.; Lu, M.; Ha, N.-C.; Quan, C.; Nam, K.H.; et al. Structural and Functional Analysis of the Pyridoxal Phosphate Homeostasis Protein YggS from *Fusobacterium nucleatum*. *Molecules* 2022, 27, 4781.

25. Jansonius, J.N. Structure, Evolution and Action of Vitamin B6-Dependent Enzymes. *Curr. Opin. Struct. Biol.* 1998, 8, 759–769.

26. Eliot, A.C.; Kirsch, J.F. Pyridoxal Phosphate Enzymes: Mechanistic, Structural, and Evolutionary Considerations. *Annu. Rev. Biochem.* 2004, 73, 383–415.

27. Parra, M.; Stahl, S.; Hellmann, H. Vitamin B6 and Its Role in Cell Metabolism and Physiology. *Cells* 2018, 7, 84.

28. Palm, D.; Klein, H.W.; Schinzel, R.; Buehner, M.; Helmreich, E.J.M. The Role of Pyridoxal 5'-Phosphate in Glycogen Phosphorylase Catalysis. *Biochemistry* 1990, 29, 1099–1107.

29. Goldin, B.R.; Frieden, C. The Effect of Pyridoxal Phosphate Modification on the Catalytic and Regulatory Properties of Bovine Liver Glutamate Dehydrogenase. *J. Biol. Chem.* 1972, 247, 2139–2144.

30. Ito, T.; Iimori, J.; Takayama, S.; Moriyama, A.; Yamauchi, A.; Hemmi, H.; Yoshimura, T. Conserved Pyridoxal Protein That Regulates Ile and Val Metabolism. *J. Bacteriol.* 2013, 195, 5439–5449.

31. Shaw, J.P.; Petsko, G.A.; Ringe, D. Determination of the Structure of Alanine Racemase from *Bacillus Stearothermophilus* at 1.9-Å Resolution, *Biochemistry* 1997, 36, 1329–1342.

32. Banner, D.W.; Bloomer, A.C.; Petsko, G.A.; Phillips, D.C.; Wilson, I.A. Atomic Coordinates for Triose Phosphate Isomerase from Chicken Muscle. *Biochem. Biophys. Res. Commun.* 1976, 72, 146–155.

33. Wierenga, R.K. The TIM-Barrel Fold: A Versatile Framework for Efficient Enzymes. *FEBS Lett.* 2001, 492, 193–198.

34. Espaillat, A.; Carrasco-López, C.; Bernardo-García, N.; Pietrosemoli, N.; Otero, L.H.; Álvarez, L.; de Pedro, M.A.; Pazos, F.; Davis, B.M.; Waldor, M.K.; et al. Structural Basis for the Broad Specificity of a New Family of Amino-Acid Racemases. *Acta Cryst. D Biol. Cryst.* 2014, 70, 79–90.

35. Fux, A.; Sieber, S.A. Biochemical and Proteomic Studies of Human Pyridoxal 5'-Phosphate-Binding Protein (Plpbp). *ACS Chem. Biol.* 2020, 15, 254–261.

36. Plecko, B.; Zweier, M.; Begemann, A.; Mathis, D.; Schmitt, B.; Striano, P.; Baethmann, M.; Vari, M.S.; Beccaria, F.; Zara, F.; et al. Confirmation of Mutations in PROSC as a Novel Cause of Vitamin B6-Dependent Epilepsy. *J. Med. Genet.* 2017, 54, 809–814.

37. Jiao, X.; Xue, J.; Gong, P.; Wu, Y.; Zhang, Y.; Jiang, Y.; Yang, Z. Clinical and Genetic Features in Pyridoxine-Dependent Epilepsy: A Chinese Cohort Study. *Dev. Med. Child. Neurol.* 2020, 62, 315–321.

38. Shiraku, H.; Nakashima, M.; Takeshita, S.; Khoo, C.S.; Haniffa, M.; Ch'ng, G.S.; Takada, K.; Nakajima, K.; Ohta, M.; Okanishi, T.; et al. PLPBP Mutations Cause Variable Phenotypes of Developmental and Epileptic Encephalopathy. *Epilepsia Open* 2018, 3, 495–502.

39. Johnstone, D.L.; Al-Shekaili, H.H.; Tarailo-Graovac, M.; Wolf, N.I.; Ivy, A.S.; Demarest, S.; Roussel, Y.; Ciapaite, J.; van Roermund, C.W.T.; Kernohan, K.D.; et al. PLPHP Deficiency: Clinical, Genetic, Biochemical, and Mechanistic Insights. *Brain* 2019, 142, 542–559.

40. Jensen, K.V.; Frid, M.; Stödberg, T.; Barbaro, M.; Wedell, A.; Christensen, M.; Bak, M.; Ek, J.; Madsen, C.G.; Darin, N.; et al. Diagnostic Pitfalls in Vitamin B6-Dependent Epilepsy Caused by Mutations in the PLPBP Gene. *JIMD Rep.* 2019, 50, 1–8.

41. Darin, N.; Reid, E.; Prunetti, L.; Samuelsson, L.; Husain, R.A.; Wilson, M.; el Yacoubi, B.; Footitt, E.; Chong, W.K.; Wilson, L.C.; et al. Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy. *Am. J. Hum. Genet.* 2016, 99, 1325–1337.

42. Espinoza, A.C.; Wright, M.A.; Candee, M.S.; Trandafir, C.; Nelson, G.R. Child Neurology: Late-Onset Vitamin B6-Dependent Epilepsy Identified by Rapid Genome Sequencing. *Neurology* 2021, 96, 911–914.

43. Heath, O.; Pitt, J.; Mandelstam, S.; Kuschel, C.; Vasudevan, A.; Donoghue, S. Early-Onset Vitamin B6-Dependent Epilepsy Due to Pathogenic PLPBP Variants in a Premature Infant: A Case Report and Review of the Literature. *JIMD Rep.* 2021, 58, 3–11.

44. Johannsen, J.; Bierhals, T.; Deindl, P.; Hecher, L.; Hermann, K.; Hempel, M.; Kloth, K.; Denecke, J. Excessive Seizure Clusters in an Otherwise Well-Controlled Epilepsy as a Possible Hallmark of Untreated Vitamin B6-Responsive Epilepsy Due to a Homozygous PLPBP Missense Variant. *J. Pediatr. Genet.* 2019, 08, 222–225.

Retrieved from <https://encyclopedia.pub/entry/history/show/75881>